Alopecia antibody deficiency

Alopecia-antibody deficiency syndrome (also known as alopecia universalis with antibody deficiency or alopecia-immunodeficiency syndrome; Orphanet code 1006) is an extremely rare genetic disorder characterized by the combination of total or near-total hair loss (alopecia universalis) and primary immunodeficiency due to defective antibody (immunoglobulin) production. The condition affects both the integumentary system (skin and hair) and the immune system. Patients typically present in early childhood with complete absence of scalp and body hair alongside recurrent infections, particularly of the respiratory and gastrointestinal tracts, resulting from impaired humoral immunity. The immunodeficiency component is classified under other immunodeficiencies with predominantly antibody defects (ICD-10: D80.8). Affected individuals may have reduced levels of one or more immunoglobulin classes, leading to increased susceptibility to bacterial infections. The alopecia is typically congenital or develops in early childhood and is usually universal, affecting all hair-bearing areas of the body. Treatment is primarily supportive and directed at managing the immunodeficiency. Immunoglobulin replacement therapy (intravenous or subcutaneous) is the mainstay of treatment for the antibody deficiency, helping to reduce the frequency and severity of infections. Prophylactic antibiotics may also be used. There is currently no established curative treatment for the alopecia component of this syndrome. Patients require long-term follow-up by both immunology and dermatology specialists. Genetic counseling is recommended for affected families.

Common questions about Alopecia antibody deficiency